Invo BioScience Debt to Equity Ratio 2010-2024 | NAYA
Current and historical debt to equity ratio values for Invo BioScience (NAYA) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Invo BioScience debt/equity for the three months ending June 30, 2024 was 0.00.
| Invo BioScience Debt/Equity Ratio Historical Data |
| Date |
Long Term Debt |
Shareholder's Equity |
Debt to Equity Ratio |
| 2024-06-30 |
$0.02B |
$0.00B |
12.23 |
| 2024-03-31 |
$0.02B |
$0.00B |
1794.86 |
| 2023-12-31 |
$0.02B |
$0.00B |
22.40 |
| 2023-09-30 |
$0.02B |
$0.00B |
51.24 |
| 2023-06-30 |
$0.01B |
$-0.00B |
-4.89 |
| 2023-03-31 |
$0.01B |
$0.00B |
68.51 |
| 2022-12-31 |
$0.01B |
$-0.00B |
-5.20 |
| 2022-09-30 |
$0.00B |
$0.00B |
2.63 |
| 2022-06-30 |
$0.00B |
$0.00B |
0.91 |
| 2022-03-31 |
$0.00B |
$0.01B |
0.52 |
| 2021-12-31 |
$0.00B |
$0.01B |
0.43 |
| 2021-09-30 |
$0.01B |
$0.00B |
2.46 |
| 2021-06-30 |
$0.01B |
$0.00B |
1.28 |
| 2021-03-31 |
$0.01B |
$0.01B |
0.82 |
| 2020-12-31 |
$0.01B |
$0.01B |
0.91 |
| 2020-09-30 |
$0.01B |
$-0.00B |
-1.43 |
| 2020-06-30 |
$0.01B |
$-0.00B |
-1.64 |
| 2020-03-31 |
$0.01B |
$-0.00B |
-1.22 |
| 2019-12-31 |
$0.01B |
$-0.00B |
-1.48 |
| 2019-09-30 |
$0.01B |
$-0.00B |
-1.68 |
| 2019-06-30 |
$0.01B |
$-0.00B |
-2.08 |
| 2019-03-31 |
$0.01B |
$-0.00B |
-2.13 |
| 2018-12-31 |
$0.00B |
$-0.00B |
-1.29 |
| 2018-09-30 |
$0.01B |
$-0.00B |
-1.21 |
| 2018-06-30 |
$0.01B |
$-0.00B |
-1.28 |
| 2018-03-31 |
$0.01B |
$-0.01B |
-1.06 |
| 2017-12-31 |
$0.01B |
$-0.01B |
-1.05 |
| 2017-09-30 |
$0.01B |
$-0.01B |
-1.04 |
| 2017-06-30 |
$0.01B |
$-0.01B |
-1.04 |
| 2017-03-31 |
$0.01B |
$-0.01B |
-1.04 |
| 2016-12-31 |
$0.01B |
$-0.01B |
-1.06 |
| 2016-09-30 |
$0.01B |
$-0.00B |
-1.09 |
| 2016-06-30 |
$0.01B |
$-0.00B |
-1.11 |
| 2016-03-31 |
$0.00B |
$-0.00B |
-1.14 |
| 2015-12-31 |
$0.00B |
$-0.00B |
-1.15 |
| 2015-09-30 |
$0.00B |
|
0.00 |
| 2015-06-30 |
$0.00B |
|
0.00 |
| 2015-03-31 |
$0.00B |
|
0.00 |
| 2011-12-31 |
$0.00B |
$-0.00B |
-1.04 |
| 2011-09-30 |
$0.00B |
$-0.00B |
-1.05 |
| 2011-06-30 |
$0.00B |
$-0.00B |
-1.05 |
| 2011-03-31 |
$0.00B |
$-0.00B |
-1.06 |
| 2010-12-31 |
$0.00B |
$-0.00B |
-1.07 |
| 2010-09-30 |
$0.00B |
$-0.00B |
-1.07 |
| 2010-06-30 |
$0.00B |
$-0.00B |
-1.08 |
| 2010-03-31 |
$0.00B |
$-0.00B |
-1.09 |
| 2009-12-31 |
$0.00B |
$-0.00B |
-1.09 |
| 2009-09-30 |
$0.01B |
$-0.01B |
-1.10 |
| 2009-06-30 |
$0.00B |
$-0.00B |
-1.18 |
| 2009-03-31 |
$0.00B |
$-0.00B |
-1.28 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.004B |
$0.003B |
|
INVO Bioscience is a medical device company, headquartered in Beverly, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. It engages in the development and manufacture of its lead product, INVOcell, a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman's vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. INVO Bioscience focuses on selling its product to IVF centers and physicians through distributors, as well as directly to physicians in Europe, Canada, Latin America, and the Middle East.
|
